HCWB (HCW Biologics) Other Stockholders Equity: $-0.00 Mil (As of Mar. 2026)


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $5.20
GF Value $7.29
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Other Stockholders Equity?

HCW Biologics HCWB -15.77% 39 Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Modestly Undervalued). The stock has 7 warning signs investors should review.

HCW Biologics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.00 Mil.

HCW Biologics's quarterly Other Stockholders Equity increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil) but then declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($-0.00 Mil).

HCW Biologics's annual Other Stockholders Equity stayed the same from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then increased from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).

HCW Biologics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for HCW Biologics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCW Biologics Other Stockholders Equity Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial -0.00 0.00 -0.00 -0.00 0.00

HCW Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00
HCWB
39GF Score
HCW Biologics Inc HCWB
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCW Biologics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
HCW Biologics (HCWB) has a Other Stockholders Equity of $-0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on HCW Biologics and its competitors.
Is HCW Biologics' Other Stockholders Equity too high?
HCW Biologics' current Other Stockholders Equity is $-0.00 Mil. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Other Stockholders Equity compare to KAPA and IMNN?
HCW Biologics' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on HCW Biologics and its competitors. HCW Biologics's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.29, compared to a current price of $5.20 — trading 28.7% below its estimated fair value. The current Other Stockholders Equity is $-0.00 Mil. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $5.20 is trading 28.7% below its estimated GF Value™ of $7.29. GuruFocus considers HCW Biologics to be Modestly Undervalued.

Key valuation signals for HCWB:

  • Other Stockholders Equity: $-0.00 Mil
  • GF Value™: $7.29 vs. price of $5.20 (28.7% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.20
Price
$7.29
GF Value